** Shares of New Zealand's Fisher & Paykel Healthcare Corp FPH.NZ up 1% at NZ$36.53
** The medical equipment maker to report FY25 results on Wednesday
** Morgan Stanley expects FY26 NPAT forecast of NZ$422 million ($253.16 million) vs Visible Alpha estimate of NZ$426 million
** Brokerage says FY26 forecasts imply limited gross margin expansion due to expected U.S. tariff impacts on products manufactured in New Zealand
** MS to focus on impacts from most recent U.S. flu season and trends for new applications growth in co's hospitals segment
** Brokerage also looking for co's updates on newer mask launches and commentary on potential impact of GLP-1s on the obstructive sleep apnea (OSA) market
** Stock rated "equal-weight" with a price target of NZ$36.7
** Fisher & Paykel down 5.1% YTD, including current session's moves
($1 = 1.6669 New Zealand dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.